OM #6

The ALLSTAR Phase II Trial randomized 142 patients who had previously experienced a heart attack, and treated 134 with either the cell therapeutic CAP-1002 or placebo. An interim analysis determined that the trial was unlikely to reach its pre-defined primary efficacy endpoint; however, bioactivity was observed in other efficacy endpoints and the product was well-tolerated in the 90 patients exposed to CAP-1002.